长药控股(300391) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥59,091,762.31, a decrease of 56.80% compared to ¥136,792,880.94 in the same period last year[5] - The net loss attributable to shareholders was ¥47,505,902.27, representing a 106.92% increase in losses from ¥22,958,141.64 year-on-year[5] - Net loss for Q1 2024 was ¥81,120,269.42, compared to a net loss of ¥30,813,220.72 in Q1 2023, representing a significant increase in losses[21] - Basic and diluted earnings per share for Q1 2024 were both -¥0.1356, compared to -¥0.0655 in the previous year[22] Cash Flow - The net cash flow from operating activities was negative at ¥32,816,721.93, a decline of 234.82% compared to a positive cash flow of ¥24,341,147.26 in the previous year[5] - Cash inflow from operating activities totaled 59,812,629.83, down 76% from 249,772,840.34 in the previous period[24] - Cash outflow from operating activities increased to 92,629,351.76, compared to 225,431,693.08 in the previous period, reflecting higher operational costs[24] - The ending cash and cash equivalents balance decreased to 2,316,745.24 from 6,054,431.45 in the previous period, indicating liquidity challenges[25] - The company received 10,250,000.00 in cash from borrowings, which was not present in the previous period, suggesting new financing efforts[25] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥3,431,968,428.54, a slight decrease of 0.40% from ¥3,445,757,061.65 at the end of the previous year[5] - Total liabilities increased to ¥2,495,767,268.42 from ¥2,428,435,632.11, indicating a rise in financial obligations[18] - The company has a total net asset of RMB 195,121,069.28, with an accumulated loss of RMB 961,745,688.98 and a net profit of RMB -605,653,315.00 for the fiscal year 2023[15] Operational Performance - The weighted average return on net assets was -27.72%, a significant drop from -2.91% in the same period last year[5] - The company’s cash flow from operating activities has been negative for two consecutive years, raising concerns about its ability to continue as a going concern[15] - The company reported a significant increase in interest expenses, totaling ¥12,788,662.59, compared to ¥9,478,334.98 in Q1 2023[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,974[10] - The largest shareholder, Changxing Shengshi Fenghua, holds 10.11% of the shares, amounting to 35,423,600 shares, with 21,002,800 shares pledged[10] Research and Development - Research and development expenses decreased by 51.33% to ¥978,777.88 from ¥2,011,134.43 year-on-year, attributed to business delays due to funding issues[8] - Research and development expenses for Q1 2024 were ¥978,777.88, a decrease of 51.4% from ¥2,011,134.43 in the same period last year[20] Fund Occupation and Risks - The company reported a significant fund occupation of RMB 179,662,019.54, accounting for 92.08% of the latest audited net assets attributable to shareholders[12] - The company is at risk of receiving additional warnings on stock trading if it fails to resolve the fund occupation issue by May 30, 2024[14] - The company plans to resolve the fund occupation issue through a debt transfer agreement, which has been approved by the board and awaits shareholder approval[14] Inventory and Receivables - Accounts receivable stood at RMB 1,603,853,809.90, slightly decreasing from RMB 1,639,156,949.32[16] - The company has a total of RMB 53,704,389.97 in inventory, which increased from RMB 51,858,189.15[16] - The company’s prepayments increased to RMB 145,416,454.20 from RMB 120,759,307.99[16]